CD22 and diffuse large B-cell lymphoma: Clinical trials NCT04088890 and ChiCTR1800019298 showed safety and efficacy data for CD22-targeted CAR-T cells in patients with r/r high-risk large B-cell lymphoma (LBCL) and diffuse large B-cell lymphoma (DLBCL) after failure of CD19-targeted CAR-T therapy.